Osteogenesis imperfecta is a genetic disorder characterized by brittle bones and increased bone fractures. The major symptoms includes frequent fractures, skeletal abnormalities, weak bones, hearing loss and short stature. The available treatment options includes bisphosphonate therapy, physical therapy, braces and corrective surgery which helps in managing the symptoms but does not cure the disorder. Recently gene therapy has emerged as a promising treatment approach which targets the underlying cause of the disease. Gene therapy involves delivery of normal collagen genes into the patient's cells using viral or non-viral vectors to correct the defective gene responsible for causing osteogenesis imperfecta. This helps in production of normal type I collagen and improved bone strength and quality.
Market key trends:
Advancement in gene therapy has accelerated the market growth of osteogenesis imperfecta treatment. Many gene therapy clinical trials are currently underway to establish safety and efficacy. In 2021, BioSenic received orphan drug designation from FDA for its lead gene therapy candidate BSN-501 which aims to deliver functional COL1A1 genes to produce normal type 1 collagen. Positive results from ongoing clinical studies can drive the market upon regulatory approval and commercialization of first gene therapy for this rare genetic disease. This will provide patients an effective treatment alternative to manage their symptoms and improve quality of life.
Segment Analysis
The global osteogenesis imperfecta treatment market is segmented based on type, treatment, end-user, and region. Based on type, the market is divided into type 1, type 3, and type 4. Type 1 dominates the market as it is the most common form of osteogenesis imperfecta, affecting nearly 60% of those diagnosed with the condition.
Key Takeaways
The Global Osteogenesis Imperfecta Treatment Market Size is expected to witness high growth. The global Osteogenesis Imperfecta Treatment Market is estimated to be valued at US$ 722.8 Mn in 2023 and is expected to exhibit a CAGR of 14% over the forecast period 2023 to 2030.
The North America region currently dominates the market and is expected to continue its dominance over the forecast period. This is attributed to growing research and development activities, rising healthcare expenditure, and presence of major players in the region. The Asia Pacific region is expected to be the fastest growing market over the forecast period. Factors such as growing healthcare expenditure, increasing patient population, rising awareness about osteogenesis imperfecta, and expanding healthcare infrastructure are expected to support the growth of the market in this region.
Key players
Key players operating in the osteogenesis imperfecta treatment market are BioSenic SA, Mereo Biopharma Group PLC, CELGENE CORPORATION, Eli Lilly and Company, Cipla Inc., Amgen Inc., Sun Pharmaceutical Industries Ltd., Viatris Inc., Teva Pharmaceutical Industries Ltd., Merck & Co., Inc., Jubilant Pharmova Limited, Aurobindo Pharma, Quince, Ultragenyx Pharmaceutical Inc. and OrthoPediatrics Corp.
Explore more information on this topic, Please visit -
https://www.insightprobing.com/osteogenesis-imperfecta-treatment-market-share-and-demand-analysis/
Comments
0 comment